Stockscreener 앱 받기
7.94
3.76%
-0.31
시간 외 거래:
7.92
-0.02
-0.25%
전일 마감가:
$8.25
열려 있는:
$8.4
하루 거래량:
115.91K
Relative Volume:
3.05
시가총액:
$16.48M
수익:
-
순이익/손실:
$-4.85M
주가수익비율:
-25.61
EPS:
-0.31
순현금흐름:
$-3.95M
1주 성능:
-28.53%
1개월 성능:
-32.14%
6개월 성능:
-39.53%
1년 성능:
-30.66%
1일 변동 폭
$7.8292
$8.9136
1주일 범위
$7.425
$12.50
52주 변동 폭
$7.425
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
명칭
Cadrenal Therapeutics Inc
전화
904-300-0701
주소
822 A1A NORTH, PONTE VEDRA
CVKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
7.94 | 17.13M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-18 | 개시 | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Cadrenal Therapeutics to conduct partnering and investor meetings - marketscreener.com
Cadrenal Therapeutics To Conduct Partnering And Investor Meetings - TradingView — Track All Markets
Cadrenal Therapeutics, Inc. Management to Hold Investor and Partner Meetings at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Biotech developing new blood thinners meets partners at major health event - Stock Titan
Cadrenal Therapeutics announces new securities purchase agreement - MSN
Cadrenal Therapeutics Announces New Securities Purchase Agreement - TipRanks
Understanding the Setup: (CVKD) and Scalable Risk - news.stocktradersdaily.com
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
CVKDCadrenal Therape Latest Stock News & Market Updates - Stock Titan
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - The Joplin Globe
Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - ACCESS Newswire
Cadrenal Therapeutics (NASDAQ: CVKD) builds multi-asset anticoagulation platform in $40B market - Stock Titan
Cadrenal Therapeutics acquires late-stage drug assets from Maryland biotech - The Business Journals
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox - Investing.com
Cadrenal Therapeutics Acquires VLX-1005 from Veralox - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox By Investing.com - Investing.com Canada
Cadrenal Therapeutics acquires VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for patients with heparin-induced thrombocytopenia - marketscreener.com
Cadrenal Therapeutics (Nasdaq: CVKD) adds Phase 2 12-LOX HIT therapy with FDA Fast Track - Stock Titan
Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga
Aug Gainers: Can Cadrenal Therapeutics Inc stock deliver strong Q4 earnings2025 Sector Review & Daily Momentum Trading Reports - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock safe for conservative investorsGap Up & Weekly Market Pulse Updates - Newser
Why Cadrenal Therapeutics Inc. stock attracts global investorsGap Up & Fast Entry Momentum Trade Alerts - Newser
The Technical Signals Behind (CVKD) That Institutions Follow - news.stocktradersdaily.com
Can Cadrenal Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser
Cadrenal Therapeutics, Inc. (CVKD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
Cadrenal Therapeutics appoints Dr. Lee Golden to board of directors - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Golden to Board - TipRanks
Cadrenal Therapeutics Appoints New Director - TradingView
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
Cadrenal Therapeutics, Inc. Appoints Lee Scott Golden, M.D. as Independent Director and Member of Science and Technology Committee - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - Sahm
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikes2025 Risk Factors & Real-Time Volume Spike Alerts - BỘ NỘI VỤ
Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis - MarketBeat
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosWeekly Investment Summary & Smart Allocation Stock Tips - BỘ NỘI VỤ
Precision Trading with Cadrenal Therapeutics Inc. (CVKD) Risk Zones - news.stocktradersdaily.com
Why Cadrenal Therapeutics Inc. stock could see breakout soonJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
Institutional scanner results for Cadrenal Therapeutics Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Is Cadrenal Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Safe Entry Zone Tips - newser.com
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award - The Manila Times
Agilent Technologies (NYSE: A) Debuts Altura Ultra Inert HPLC With 2x Sensitivity - Stock Titan
Detecting price anomalies in Cadrenal Therapeutics Inc. with AITreasury Yields & Fast Gaining Stock Reports - newser.com
What the charts say about Cadrenal Therapeutics Inc. todayWatch List & Daily Stock Trend Watchlist - newser.com
Is Cadrenal Therapeutics Inc. stock attractive for retirement portfolios2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Cadrenal Therapeutics Receives Legal Opinion From Blank Rome LLP On ?Validity Of Share Offering - MarketScreener
Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks
Cadrenal Therapeutics IncBlank Rome LLP issued legal opinion on $3,438,062 sharesSEC filing - MarketScreener
[8-K] Cadrenal Therapeutics, Inc. Reports Material Event | CVKD SEC FilingForm 8-K - Stock Titan
Cadrenal Therapeutics Inc (CVKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):